These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

840 related items for PubMed ID: 8855790

  • 1. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
    Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R.
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
    [Abstract] [Full Text] [Related]

  • 2. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J.
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [Abstract] [Full Text] [Related]

  • 3. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ, Chesnut CH, Mallinak NJ.
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [Abstract] [Full Text] [Related]

  • 4. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM, Parviainen M, Niskanen L, Komulainen M, Tuppurainen MT, Kröger H, Saarikoski S.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [Abstract] [Full Text] [Related]

  • 5. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 6. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
    Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW.
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
    [Abstract] [Full Text] [Related]

  • 7. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
    Eviö S, Tiitinen A, Laitinen K, Ylikorkala O, Välimäki MJ.
    J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
    [Abstract] [Full Text] [Related]

  • 8. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [Abstract] [Full Text] [Related]

  • 9. Biochemical markers as predictors of rates of bone loss after menopause.
    Rogers A, Hannon RA, Eastell R.
    J Bone Miner Res; 2000 Jul; 15(7):1398-404. PubMed ID: 10893690
    [Abstract] [Full Text] [Related]

  • 10. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF, Margioris AN, Dretakis KE, Trovas G, Zoras U, Lyritis G, Dretakis EK, Stergiopoulos K.
    Maturitas; 2004 Mar 15; 47(3):185-93. PubMed ID: 15036488
    [Abstract] [Full Text] [Related]

  • 11. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD.
    J Bone Miner Res; 1996 Mar 15; 11(3):337-49. PubMed ID: 8852944
    [Abstract] [Full Text] [Related]

  • 12. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.
    Bone; 2010 Apr 15; 46(4):935-9. PubMed ID: 20060081
    [Abstract] [Full Text] [Related]

  • 13. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
    Chaki O, Yoshikata I, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara F, Gorai I.
    J Bone Miner Res; 2000 Aug 15; 15(8):1537-44. PubMed ID: 10934652
    [Abstract] [Full Text] [Related]

  • 14. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 15; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 15. Bone turnover markers and bone density across the menopausal transition.
    Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, Wark JD.
    J Clin Endocrinol Metab; 1996 Sep 15; 81(9):3366-71. PubMed ID: 8784098
    [Abstract] [Full Text] [Related]

  • 16. Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type Ib.
    Tollin SR, Perlmutter S, Aloia JF.
    J Bone Miner Res; 2000 Jul 15; 15(7):1412-6. PubMed ID: 10893692
    [Abstract] [Full Text] [Related]

  • 17. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
    Guo CY, Weetman AP, Eastell R.
    Clin Endocrinol (Oxf); 1997 Mar 15; 46(3):301-7. PubMed ID: 9156039
    [Abstract] [Full Text] [Related]

  • 18. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.
    Minisola S, Pacitti MT, Rosso R, Pellegrino C, Ombricolo E, Pisani D, Romagnoli E, Damiani C, Aliberti G, Scarda A, Mazzuoli SF.
    J Endocrinol Invest; 1997 Oct 15; 20(9):559-65. PubMed ID: 9413811
    [Abstract] [Full Text] [Related]

  • 19. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.
    Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG.
    J Clin Endocrinol Metab; 2000 Jun 15; 85(6):2197-202. PubMed ID: 10852452
    [Abstract] [Full Text] [Related]

  • 20. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul 15; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.